Cipla Reports Record Revenue; Shares Surge 5% Following Q4 Results
Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue
Business Standard
Image: Business Standard
Cipla's shares rose nearly 5% to ₹1,353.80 after the company announced a record annual revenue of ₹28,163 crore for fiscal year 2026, despite a decline in Q4 earnings. The pharmaceutical giant's performance was bolstered by robust growth in its One India business and steady demand in North America.
- 01Cipla's shares increased by nearly 5% following the announcement of record annual revenue.
- 02The company reported total income of ₹6,541 crore in Q4 FY26, down 2.8% year-on-year.
- 03Cipla's full-year revenue reached ₹28,163 crore, marking a 2.23% increase from the previous fiscal.
- 04The One India business achieved over ₹12,500 crore in annual revenue, with strong growth in key segments.
- 05Cipla's North America revenue for the quarter was $155 million, contributing to overall performance.
Advertisement
In-Article Ad
Cipla, a global pharmaceutical company, saw its shares jump nearly 5% to an intraday high of ₹1,353.80 on the National Stock Exchange (NSE) following the announcement of its highest-ever yearly revenue of ₹28,163 crore for fiscal year 2026. Despite this success, the company reported a 2.8% decline in total income from operations for the March 2026 quarter, totaling ₹6,541 crore. Earnings before interest, tax, depreciation, and amortisation (Ebitda) also fell 35.17% to ₹997 crore. The profit after tax for Q4 FY26 was ₹555 crore, a significant drop of 54.6% from the previous year. However, Cipla's full-year profit after tax rose to ₹5,273 crore, up from ₹3,879 crore in FY25. The One India business showed strong growth, surpassing ₹12,500 crore in annual revenue, while the North America segment generated $155 million in quarterly revenue. Cipla's management highlighted ongoing investments in research and development, amounting to ₹509 crore, or 7.8% of sales, and expressed optimism about future growth in key markets.
Advertisement
In-Article Ad
Cipla's record revenue and strong performance in key segments could lead to increased investor confidence and potential growth in the pharmaceutical sector, benefiting employees and stakeholders.
Advertisement
In-Article Ad
Reader Poll
Do you believe Cipla will continue to grow in the coming fiscal year?
Connecting to poll...
More about Cipla
Read the original article
Visit the source for the complete story.